HLA Antibody Incompatible Renal Transplantation: Long-term Outcomes Similar to Deceased Donor Transplantation.
Krishnan, Nithya Abimbola, Aisha Machan, Nandhini Daga, Sunil Gopalakrishnan, Kishore Lam, ForTai Tan, LamChin Kashi, Habib Zehnder, Daniel Collins, Claire
Krishnan, Nithya
Abimbola, Aisha
Machan, Nandhini
Daga, Sunil
Gopalakrishnan, Kishore
Lam, ForTai
Tan, LamChin
Kashi, Habib
Zehnder, Daniel
Collins, Claire
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2021-07-19
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The overall patient survival was 95%, 90%, and 81%; and graft survival was 95%, 85%, and 70% at 1, 5, and 10 y, respectively. This was similar to the first-time deceased donor transplant cohort. The graft survival for pretreatment cytotoxic-dependent crossmatch (CDC) positive crossmatch group was significantly low at 83%, 64%, and 40% at 1, 5, and 10 y, respectively, compared with other groups (Bead/CDC, P = 0.007; CDC/Flow, P = 0.001; and microbead assay/flow cytometry crossmatch, P = 0.837), although those with a low CDC titer (<1 in 2) have comparable outcomes to the CDC negative group. Female patients in general fared worse in both patient and graft survival outcomes in each of the 3 groups based on pretreatment crossmatch, although this did not reach statistical significance. Antibody-mediated rejection was the most frequent type of rejection with significant decline in graft survival by 10 y when compared with no rejection (P < 0.001). Rejection that occurred or continued to occur after the first 2 wk of transplantation caused a significant reduction in graft survivals (P < 0.001), whereas good outcomes were seen in those with a single early rejection episode.
Citation
Transplant Direct . 2021 Jul 19;7(8):e732
Type
Article